MRNA · 8-K · 20260731PR000147
Manufacturing And Capacity
Moderna, Inc. · 2026-07-31 · Importance 52 · Surprise 42 · In source text
Moderna incurred $23 million of unutilized manufacturing-capacity costs in the second quarter, indicating that production capacity remained underused. Unutilized-capacity costs declined from the prior year as continued manufacturing productivity improvements and operational efficiencies reduced excess-capacity costs. The company also recorded $41 million of inventory write-downs, reflecting product and inventory-management pressure. The Brazilian manufacturer collaboration and the U.K. government-partnership deliveries provide additional production and supply channels for COVID vaccines.
Key facts
- Unutilized manufacturing capacity costs included in cost of sales for the second quarter of 2026 were $23 million. source
- Moderna expects cost discipline and continued manufacturing productivity improvements and operational efficiencies to contribute to lower unutilized manufacturing capacity costs. source
- Property, plant and equipment, net as of June 30, 2026 was $2,059 million. source
- Inventory as of June 30, 2026 was $280 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -15.9% | Unutilized manufacturing capacity costs included in cost of sales for the second quarter of 2026 were $23 million. |
| operating_income | positive | probable | — | Moderna expects cost discipline and continued manufacturing productivity improvements and operational efficiencies to contribute to lower… |